Ladenburg Thalmann Financial Services Reiterates “$54.00” Price Target for Mazor Robotics Ltd. (MZOR)
Ladenburg Thalmann Financial Services set a $54.00 price objective on Mazor Robotics Ltd. (NASDAQ:MZOR) in a research note released on Wednesday. The brokerage currently has a buy rating on the medical instruments supplier’s stock.
MZOR has been the topic of several other research reports. JMP Securities downgraded Mazor Robotics from an outperform rating to a market perform rating in a research report on Friday, May 12th. They noted that the move was a valuation call. Needham & Company LLC restated a hold rating on shares of Mazor Robotics in a research report on Thursday, July 6th. Zacks Investment Research downgraded Mazor Robotics from a hold rating to a sell rating in a research report on Tuesday, July 18th. Wells Fargo & Company downgraded Mazor Robotics from an outperform rating to a market perform rating in a research report on Thursday, May 11th. Finally, ValuEngine upgraded Mazor Robotics from a sell rating to a hold rating in a research report on Friday, June 2nd. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and two have given a buy rating to the company’s stock. The company presently has an average rating of Hold and an average target price of $37.33.
Mazor Robotics (MZOR) traded up 4.15% during mid-day trading on Wednesday, reaching $49.23. The company had a trading volume of 301,746 shares. The company’s 50-day moving average is $39.58 and its 200-day moving average is $34.25. The stock’s market capitalization is $1.19 billion. Mazor Robotics has a one year low of $20.19 and a one year high of $49.64.
Mazor Robotics (NASDAQ:MZOR) last posted its earnings results on Tuesday, August 1st. The medical instruments supplier reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.09. The firm had revenue of $15.46 million for the quarter, compared to the consensus estimate of $15.38 million. Mazor Robotics had a negative return on equity of 28.51% and a negative net margin of 37.66%. The business’s quarterly revenue was up 86.7% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.09) earnings per share. Equities research analysts anticipate that Mazor Robotics will post ($0.75) earnings per share for the current year.
Several large investors have recently modified their holdings of the company. Dimensional Fund Advisors LP increased its stake in shares of Mazor Robotics by 8.1% in the second quarter. Dimensional Fund Advisors LP now owns 8,570 shares of the medical instruments supplier’s stock worth $296,000 after buying an additional 641 shares during the period. Royal Bank of Canada increased its stake in shares of Mazor Robotics by 9.2% in the second quarter. Royal Bank of Canada now owns 21,663 shares of the medical instruments supplier’s stock worth $749,000 after buying an additional 1,819 shares during the period. UBS Group AG increased its stake in shares of Mazor Robotics by 2.4% in the first quarter. UBS Group AG now owns 99,954 shares of the medical instruments supplier’s stock worth $2,976,000 after buying an additional 2,379 shares during the period. Quantbot Technologies LP acquired a new stake in shares of Mazor Robotics during the second quarter worth about $135,000. Finally, JPMorgan Chase & Co. increased its stake in shares of Mazor Robotics by 398.5% in the first quarter. JPMorgan Chase & Co. now owns 6,979 shares of the medical instruments supplier’s stock worth $208,000 after buying an additional 5,579 shares during the period. Institutional investors own 27.52% of the company’s stock.
Mazor Robotics Company Profile
Mazor Robotics Ltd is an Israel-based medical device company that develops and markets surgical guidance systems and complementary products. It develops computerized and imaging-based systems in the field of spine surgery. Its products include: Renaissance Surgical Guidance System, which enables surgeons to advance from freehand surgical procedures to guided procedures, as well as Food and Drug Administration (FDA)-cleared and European Conformity (CE)-marked Renaissance System, used in spine surgeries, whether open or minimally invasive, for a number of clinical indications.
Receive News & Ratings for Mazor Robotics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mazor Robotics Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.